A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring

ClinicalTrials.gov ID: NCT06710470

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06710470. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Deucravacitinib Pregnancy Study: A Retrospective Observational Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This observational study aims to assess pregnancy and infant outcomes among pregnant women with psoriasis who have been exposed to deucravacitinib treatment in the USA.

Study identification

NCT ID: NCT06710470
Recruitment status: Active, not recruiting
Study type: Observational
Phase: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 833 participants

Conditions and interventions

Conditions

Psoriasis

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 15 Years to 50 Years
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 2, 2024 (Actual)
Primary completion: Jan 31, 2027 (Estimated)
Completion: Feb 28, 2029 (Estimated)
Last update posted: Nov 29, 2024

2024 – 2029

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Bristol-Meyers Squibb	Lawrenceville	New Jersey	08648	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06710470, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 29, 2024 · Synced Nov 13, 2026